Journal of Immunology Research

Journal of Immunology Research / 2016 / Article
!A Corrigendum for this article has been published. To view the article details, please click the ‘Corrigendum’ tab above.

Review Article | Open Access

Volume 2016 |Article ID 9720912 | 12 pages |

New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy

Academic Editor: Eyad Elkord
Received20 Jun 2016
Accepted26 Sep 2016
Published16 Nov 2016


The majority of basic and clinical studies have shown a protumor function of tumor-associated macrophages (TAMs), which represent a large proportion of matrix cells. TAMs promote tumorigenesis, and their number is related to the malignancy degree and poor prognosis of many kinds of tumors. Macrophage plasticity makes it possible to change the tumor microenvironment and remodel antitumor immunity during cancer immunotherapy. Increasing numbers of studies have revealed the effects of TAMs on the tumor microenvironment, for example, via promotion of tumor growth and tumorigenesis and through an increase in the number of cancer stem cells or via facilitation of angiogenesis, lymphangiogenesis, and metastasis. Investigators also proposed tumor-immunological treatments targeting TAMs by inhibiting TAM recruitment and differentiation, by regulating TAM polarization, and by blocking factors and pathways associated with the protumor function of TAMs. This comprehensive review presents recent research on TAMs in relation to prediction of poor outcomes, remodeling of the tumor immune microenvironment, and immunological targeted therapies.

1. Introduction

Macrophages are differentiated cells of the mononuclear phagocytic lineage. They are heterogeneous cells with distinct functions and respond differently to various microenvironmental signals and thus have distinct functions. Macrophages—derived from hematopoietic stem cells in bone marrow or from progenitor cells in the embryonal yolk sac—differentiate into two distinct types of macrophages (M), classically activated or M1 M (“killing” phenotype) and alternatively activated or M2 M (“healing” phenotype). Tumor-associated macrophages (TAMs) may represent up to 50% of the tumor mass, and most TAMs have the M2 phenotype due to the signals in the tumor microenvironment, such as IL-4 and TGF-β [1, 2]. As generally accepted at present, TAMs play a key role in tumorigenic processes ranging from tumor initiation to acceleration of tumor progression and metastasis.

2. TAMs Lead to a Poor Clinical Prognosis and Promote Progression of Various Tumors

2.1. TAMs Can Be Considered a Biomarker of Poor Prognosis

TAMs provide a suitable microenvironment for tumor invasion and progression and contribute to the metastasis of tumor cells [3]. Researchers have shown that the existence of TAMs positively correlates with a poor clinical prognosis of various tumors, such as lung cancer, gastric cancer, gynecological tumors, and lymphomas (Table 1). Although there are a few exceptions to this association, such as colorectal carcinoma [4], these data still indicate that TAMs play an essential role in tumorigenesis; accordingly, targeting of TAMs may be a promising method of cancer treatment.

CancerIHC markerPrognostic outcomeRef.

Hormone receptor-positive breast cancerIntratumoral TAMsPoor DFS[25]
Triple-negative breast cancerCD68+ TAMsPoor OS and DFS[26]
Gastric cancerCD204+ TAMs combined with Osteopontin (OPN)Poor 5-year OS[27]
Lung cancer induced malignant pleural effusion (MPE)CD163+ TAMs in MPEPoor progression-free survival[28]
Non-small cell lung cancerTAMs combined with OPNLower DFS and OS[29]
TAMs combined with IL-6, CSF-1Lower 5-year survival rate[9]
Esophageal cancer undergoing neoadjuvant chemotherapyCD68+ and CD163+ TAMsTumor depth, lymphatic invasion, venous invasion, and poor response to chemotherapy[6]
Oral squamous cell carcinomaCD68+ TAMs or combined with ALDH1, CD44, SOX2, IL-10High tumor grade, lymph node metastasis, shorter OS and DFS, and poor clinical stage[3032]
Nonfunctional pancreatic neuroendocrine tumors (NF-PNETs)CD68+ TAMs combined with Ki-67 indexHigh risk of recurrence[33]
GliomaCD206+ TAMsLower PFS and OS[34]
Colorectal cancerCD40+ TAMs or combined with urokinase-type plasminogen activator receptorLower OS, lymph node, and distant metastasis[35, 36]
Pancreatic ductal adenocarcinomaCD204+ TAMs combined with CD44/CD133Lower PFS and OS[37]
Advanced epithelial ovarian cancerCD68+ and CD163+ TAMsPoor PFS and OS[38]
Bladder carcinomaCD68+ TAMsPoor recurrence-free survival[39]
Triple-negative endometrial endometrioid adenocarcinomaCD68+ TAMs combined with overexpression of EGFRPoor OS[40]
Prostate cancerCD68+ TAMsPoorly differentiated disease but no association with biochemical recurrence after radical prostatectomy[41]
Poor OS[42]
Classical Hodgkin lymphomaCD68+ and CD163+ TAMsHigh risk of treatment failure with ABVD chemotherapy[43]
Primary central nervous system lymphoma (PCNSL)CD68+ and CD163+ TAMsInferior PFS but no association with OS[44]
Peripheral T-cell lymphomaCD68+ TAMs combined with VEGFPoor OS[45]
Diffuse large B-cell lymphomaCD68+ TAMsPoor treatment outcome and poor median survival time[46]

PFS: progression-free survival, DFS: disease-free survival, and OS: overall survival.
2.2. TAMs Reduce the Curative Effect of Chemotherapy

Chemotherapy is a conventional treatment modality for cancer patients. Although chemotherapies have strong effects on some kinds of tumors, such as small cell lung cancer [5] and lymphomas [6], the overall response rate is less than satisfactory for many tumors [7]. Furthermore, drug resistance, tumor recurrence, and metastasis make tumor treatment more difficult.

TAMs were found to help reduce the effects of chemotherapy. Infiltration by CD68+ and CD163+ TAMs is associated with a poor response to chemotherapy in patients with esophageal cancer [8, 9]. TAMs are also recruited to the pancreatic tumor site and stimulate adenocarcinoma cells to express high levels of cytidine deaminase, which catabolizes the bioactive form of gemcitabine and reduces the sensitivity of cancer cells to chemotherapy [10]. Yang et al. [11] also found that TAMs can induce chemotherapeutic drug resistance of a breast tumor through the IL-10/STAT3/Bcl-2 signaling pathway, and another study showed that TAMs correlate with the resistance to tamoxifen, an endocrine therapy drug for postmenopausal breast cancer patients [12].

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are novel treatments of lung cancer with EGFR mutation and have higher specificity and fewer side effects than traditional treatments; M2-polarized TAMs also correlate with the decreased responsiveness to EGFR-TKI treatment in patients with advanced lung adenocarcinoma [13].

2.3. TAMs Cause an Unfavorable Outcome of Radiotherapy

Radiotherapy (RT) is a localized therapy that is highly effective at killing primary tumor cells located within the field of the radiation beam. Despite sophisticated techniques for radiation delivery as well as the combination of radiation with chemotherapy, tumors can recur [14].

TAMs are abundantly recruited to tumors after irradiation and may modulate cancer cells’ responses to therapy [15]. It has been suggested that macrophages may be involved in modulating the late effects of radiotherapy [16]. Various studies indicate a correlation between high TAM numbers and poor tumor responses to irradiation in mouse models [17]. Furthermore, Shiao et al. [18] reported that regrowth of mammary tumors after radiotherapy correlates with the influx of Th2-polarized macrophages. After tumor irradiation, DNA damage, cell death, and increased tumor hypoxia may promote production of VEGF, SDF-1, and CSF-1, resulting in the recruitment, infiltration, and retention of monocytes/macrophages within the tumor [14]. The recruited heterogeneous populations of TAMs release proangiogenic cytokines and metalloproteinases to promote blood vessel formation within the tumor [19]. Teresa Pinto et al. [20] also found that irradiated macrophages promote cancer cell invasiveness and cancer cell-induced angiogenesis. Besides, the abscopal effect may be a crucial factor in evaluation of the prognosis associated with radiotherapy, and TAMs can release secondary bystander signals and play a key role in the secondary bystander effect of photon irradiation [21]. Targeting TAMs or TAM-associated signaling to enhance the potency of radiotherapy has been similarly demonstrated in several other studies [14, 2224]. Inhibition of TAM recruitment after radiotherapy by neutralizing CSF-1 or blocking CSF-1R kinase activity may significantly slow tumor regrowth [15].

3. TAMs Remodel the Tumor Microenvironment

3.1. TAMs Ensure an Immunosuppressive Tumor Microenvironment

The tumor immune microenvironment is mainly formed by such immune cells as macrophages, T lymphocytes, natural killer cells (NK cells), dendritic cells, neutrophils, and myeloid-derived suppressor cells (MDSCs) [47, 48]. As a kind of immunosuppressive cell subgroup, TAMs express chemokines and cytokines and contribute to the immunosuppressive tumor microenvironment (ITM) [49]. Chemokines (such as CCL5, CCL22, and CCL20) secreted by TAMs recruit regulatory T (Treg) cells, whereas cytokines (such as IL-10 and TGF-β) induce Treg cells. Besides, TAMs may inhibit the antitumor effect of tumor-infiltrating T cells and NK cells [50, 51] and promote ITM synergistically with MDSCs, tumor-associated dendritic cells, and neutrophils [47, 5254]. TAMs may suppress T-cell function by secreting specific enzymes such as nitric-oxide synthase (NOS) and arginase (ARGI) [55, 56]. In addition, TAMs express ligands for receptors called PD-1 and CTLA-4 (such ligands as PD-L1 and B7-H1), which after activation suppress cytotoxic functions of T cells, NKT cells, and NK cells [57].

3.2. TAMs Promote Tumorigenesis

Cancer can be considered a nonresolving inflammatory disease. Up to 20% of all cancers arise in association with chronic inflammation, and almost all solid tumors contain inflammatory infiltrates [58]. TAMs, as the major immune cells in a tumor, have a broad impact on tumor initiation. Macrophages can play contrasting roles in cancer depending on their phenotype. M1-type macrophages have the potential to contribute to the earliest stages of neoplasia, whereas M2-type macrophages usually get involved after a tumor progresses and grows [59]. DNA damage is the major mechanism of tumorigenesis induced by inflammation. The free radicals produced by TAMs can lead to DNA damage, causing mutations that predispose the affected individual to cancer. An example of this macrophage-mediated induction of tumorigenesis is that Crohn’s disease dramatically increases the risk of colorectal cancer [6063]. Besides, chronic infection with viruses such as hepatitis B virus in the liver or with bacteria like Helicobacter pylori in the stomach or continuous exposure to irritants such as asbestos in lungs is casually associated with cancer initiation.

3.3. TAMs Facilitate Metastasis

Metastasis is responsible for more than 90% of cancer mortality yet remains the least understood stage of tumor progression. TAMs have been shown to be key players in metastasis and mainly participate in several steps including epithelial-to-mesenchymal transition (EMT), local invasion and intravasation into the vasculature, transit through the circulatory system, extravasation and seeding in the premetastatic niche, and finally survival and growth at the metastatic site [64, 65]. TAMs can promote progression and metastasis through the release of a variety of chemokines, inflammatory factors, and growth factors. It is reported that CD68+HLA-DR+ TAMs in hepatocellular carcinoma (HCC) can promote migration of HCC cells via the NF-κB/FAK pathway [66]. Specifically, TAM-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner [67].

In breast tumors, TAMs are recruited to pulmonary metastases by CCL2 and enhance extravasation, seeding, and persistent growth of tumor cells in part via expression of VEGF [68]. CCL2 synthesized by a tumor and stroma also triggers a prometastatic chemokine cascade (involving CCL3 signaling via CCR1) that is required for efficient metastasis [69]. Besides, TAMs binding to VCAM-1 expressed on breast cancer cells can promote tumor cell survival in lungs [70]. The bidirectional cross-talk between cancer cells and TAMs constitutes a microanatomic landmark, which is defined as the tumor microenvironment of metastasis (TMEM), whereas TMEM density is positively associated with the risk of distant organ metastases [71].

EMT is a process via which epithelial tumor cells lose epithelial features and gain mesenchymal phenotypes [72]. EMT is considered the key step via which tumor cells gain the greater capacity for invasiveness and metastasis. TAMs can strongly express many kinds of cytokines that can induce EMT, such as TGF-β and IL-6 [73]. TNF-α secreted by TAMs has been shown to activate NF-κB-mediated transcription of Snail1 and Zeb, which leads to diminished E-cadherin expression on tumor cells [74]. One report suggests that M2 macrophages may induce EMT by regulating TLR4/IL-10 signaling in pancreatic cancer cells [75]. TAMs may also secrete EGF-like ligands/factors that activate the EGFR pathway in cancer cells, thus promoting EMT, and this macrophage-induced EMT is significantly inhibited by treatment of A549 cancer cells with JWH-015 [76].

CCL18 released from TAMs can induce EndMT in endothelial cells to produce a different differentiated phenotype, which may lead to a loss of cell-cell junctions as well as enhanced invasiveness and migratory capacity [77]. These data confirm a strong cross-talk between macrophages and tumor progression, mainly through stimulation of EMT.

3.4. TAMs Promote Angiogenesis and Lymphangiogenesis

The growth and spread of neoplasms depend on angiogenesis and lymphangiogenesis in the tumor microenvironment. With neoplastic progression, increasing numbers of blood and lymphatic vessels provide supply channels for tumor tissues. On the other hand, it is reported that these mounting vessels provide a route for the lymph-nodal and distant metastases of tumor cells [7881]. The infiltration by TAMs is associated with extensive angiogenesis, which contributes to a poor prognosis in primary cancers. Multiple factors are involved in angiogenesis: hypoxia, hyperosmosis, and proangiogenic factors such as vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-β), cyclooxygenase 2 (COX-2), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), angiopoietins (Ang), and chemokines [8286]. CCL18 released from TAMs can promote angiogenesis and tumor progression in breast cancer [70]. TAMs can also synthesize Wnt7b, which targets vascular endothelial cells by stimulating their production of VEGF resulting in the angiogenic switch [87]. One of the major angiogenesis-inducing factors, pro-matrix metalloproteinase-9 (proMMP-9), is supplied to the tumor microenvironment by TAMs [88]. It has been demonstrated that matrix metalloproteinase 9 (MMP-9) plays a crucial role in tumor angiogenesis and metastasis by turning on the angiogenic switch in avascular tumors and by mediating the development and maintenance of distinct neovascular networks sustaining tumor cell intravasation [89, 90]. Hypoxia causes a tumor microenvironment overexpressing hypoxia-inducible factor 1α (HIF-1α), the primary transcription factor involved in homeostasis of oxygen concentration. HIF-1α can activate transcription of genes encoding angiogenic growth factors and stimulating endothelial cells (ECs), thus leading to angiogenesis [75]. TAMs’ localization to hypoxic tumor areas is controlled by the Sema3A/neuropilin-1 signaling axis, leading to plexinA1/plexinA4-dependent VEGFR1 activation and promotion of tumor growth and metastasis [91]. In addition, TAMs can increase the expression of HIF-1α and promote endothelial-tube formation in colon cancer [92]. Besides, Laoui et al. found that hypoxia specifically lowers hypoxia-sensitive gene expression and angiogenic activity in the MHC- TAM subset instead of altering differentiation of the TAM population [93].

Coordination of the lymphatic microvascular network with the blood microvasculature is involved in normal physiological functions, such as local tissue fluid balance, tissue perfusion, and immune surveillance [9496], and gives more weight to lymphangiogenesis during tumor growth and cancer metastasis [72]. A number of studies have revealed lymphatic microvessel density (LMVD) to be an independent prognostic factor for solid tumors [97100]. Additionally, TAMs are reportedly involved in lymphangiogenesis in malignant tumors [101]. Zhang et al. found that TAMs in lung adenocarcinoma are associated with poor prognoses resulting from accelerated lymphangiogenesis and lymph node metastasis [102].

Tumor cells induce formation of lymphatic vessels via the lymphatic system metastasis through VEGF-C, VEGF-D, and other cytokines [103]. The expression of VEGF-C and VEGF-D by TAMs suggests that TAMs are intimately involved in the generation of tumor lymphatic vessels [104]. M2-polarized TAM infiltration of RLNs is significantly associated with nodal lymphangiogenesis, and node-infiltrating M2-polarized TAMs may facilitate nodal lymphangiogenesis via production of VEGF-C [105].

3.5. TAMs and Cancer Stem Cells (CSCs)

CSCs or cancer-initiating cells are defined as a small subpopulation of cancer cells with the capacity for self-renewal and pluripotency. CSCs are necessary for initiation of new tumor growth at distant sites. Currently, many studies support the notion that CSCs, which have many features of stem cells, are responsible for the poor prognosis of patients by promoting tumor recurrence and metastasis [106, 107].

TAMs can regulate the plasticity of CSC phenotypes and functions. Recently, some of TAMs-CSCs interrelations were confirmed experimentally. TAMs were found to release milk-fat globule EGF-VIII, which activates the CSC-specific pathways—STAT3, Hedgehog, and Sonic—and strongly amplifies drug resistance and tumorigenicity of CSCs [108]. MFG-E8 and IL-6 from TAMs can also synergistically mediate tumorigenicity and drug resistance in subsets of CSCs including those in primary human tumors [109]. In experiments with murine mammary CSCs, Yang et al. reported that drug resistance of CSCs is associated with new EGFR/STAT3/Sox-2 paracrine signaling pathway activity that is realized via a complex interplay between CSCs and TAMs [110]. It is reported that TAMs have effects on gastric CSCs in omental milky spots and on lymph node micrometastasis, which is mainly mediated by activation of MCP-1, COX-2, PGE-2, IL-10, IFN-γ, and VEGF and by downregulation of IL-4, TGF-β, MMP-2, and MMP-9 [111]. It has been suggested TAMs may promote CSC-like properties via TGF-β1-induced EMT and may advance the research on the prognosis of HCC [112]. Furthermore, microglia and brain TAMs serve as mediators of glioma stem-like cell (GSLC) properties, producing high levels of TGF-β, which makes GSLCs more invasive [113]. Direct cell-cell interactions of TAMs with CSCs via Thy1 and Eph4A receptors have been reported to induce activation of NF-κB, which in turn sustains the CSCs state [114].

The functional and phenotypic heterogeneity of CSCs themselves in turn affects the pathophysiological activities of TAMs. It seems that active CSCs should be able to promote the M1-to-M2 conversion, induce formation of new vasculature via VEGF release, and build CSC-protective niches via tissue-repair pathways [2]. OCSCs may promote the M2 polarization of macrophages through the PPARγ/NF-κB pathway [115]. Chemoresistant CSCs may promote M2 macrophage differentiation through interferon-regulatory factor-5- (IRF5-) and macrophage-colony stimulating factor- (M-CSF-) dependent mechanisms [116]. Chen et al. reported that embryonic stem cells can promote macrophage survival and M2-like activation, which are critically important for teratoma angiogenesis and development [117] (Figure 1).

TAMs can be considered a biomarker of poor prognosis and reduce the curative effect of chemotherapy and radiotherapy. In terms of mechanisms, TAMs may promote a tumor immunosuppressive microenvironment, tumorigenesis, angiogenesis, and lymphangiogenesis and can facilitate metastasis.

4. Treatments Targeting TAMs

Immunotherapy acts in a fundamentally different way in comparison with classical therapies. Rather than destroying tumor cells directly, immunotherapy promotes tumor cell killing via the immune response of the host. This result can be achieved directly via the main effectors of the immune system, such as macrophages. Evidence reviewed by Mills et al. indicates that modulation of macrophage responses is a breakthrough that will facilitate successful immunotherapy [118]. In a sorafenib-resistant tumor model, photoimmunotherapy targeting TAMs was found to inhibit the tumor growth and metastasis [119]. Therefore, TAMs have become promising therapeutic targets for cancer treatment. In recent years, many researchers focused on cancer immunotherapy related to TAMs (Table 2).

Therapeutic approachesCancerDrugsRef.

Killing TAMs or inhibiting TAM recruitment and differentiation
 Blocking the murine or human IL-4 receptor α (IL4Rα or CD124)RNA aptamer[125]
 Inducing apoptosis in TAMs via Kv1.3 and Kv1.5 potassium channelsMembrane-permeant drugs[118]
 Selectively cytotoxic for TAMs and their circulating precursors (monocytes) by activating caspase 8-dependent apoptosisSarcoma and ovarian carcinomaTrabectedin[126]
 Reducing macrophage motility, inhibiting macrophage infiltration of irradiated tumorsColon carcinomaDequalinium-14[12]
 Suppressing of tumor-associated macrophage differentiationGallbladder cancerInterferon-γ[120]
Regulation of TAM polarization
 Reversing TAM orientation and polarization from M2- to M1-type TAMsBreast cancerDimethyl sulfoxide[124]
 Reeducating CD163+ TAMs to M1 macrophages through TLR4-mediated pathwayMPEPA-MSHA[23]
 Shifting the M1/M2 TAMs balance by M-CSFR signaling blockadeLung carcinoma and breast carcinomaAnti-M-CSFR antibody[125]
 Modulating the M2/M1 macrophage ratioLung cancerIFNγ and/or celecoxib[126]
Blocking factors and pathways associated with protumor function of TAMs
 Inhibiting the paracrine loop between TAM and PCa cells via NF-κB regulationProstate cancerSomatostatin derivate (smsDX)[128]
 Suppressing chemokine (C-C motif) ligand 2 expression in tumor-associated macrophageLung carcinomaLuteolin[129]
 Inhibiting macrophage-induced EMT by downregulation of EGFR pathwayNon-small cell lung cancerCannabinoid receptor-2 agonist[69]

4.1. Killing of TAMs or Inhibition of TAM Recruitment and Differentiation

Strategies to deplete TAMs have been successful in experimental settings and are now considered a promising therapeutic approach in the clinic [120]. The current approach to targeting of TAMs that has shown efficacy is inhibition of CSF-1/CSF-1R signaling because this axis is required for macrophage survival [121, 122]. For instance, targeting of CSF-1/CSF-1R alters macrophage polarization and blocks glioma progression [123]. RG7155, a monoclonal antibody that inhibits CSF-1 receptor (CSF-1R), can provide significant clinical benefits and offer a therapeutic option other than surgical treatment to patients with a diffuse-type giant cell tumor (Dt-GCT) [124].

An RNA aptamer that blocks the murine or human IL-4 receptor-α (IL4Rα or CD124) can preferentially target TAMs and unexpectedly promote their elimination, an effect that is associated with an increased number of tumor-infiltrating T cells and a reduction in tumor growth [125]. Allavena et al. have recently demonstrated that trabectedin, a licensed and commercially available anticancer agent, is selectively toxic to TAMs because of activation of caspase 8-dependent apoptosis [126, 127]. Membrane-permeating drugs can also induce apoptosis in macrophages; this effect may be exploited for the depletion of TAMs [128]. Inhibiting recruitment of macrophages to neoplastic lesions is one of the therapies targeting TAMs. The antitumor agent dequalinium-14 in addition to its antitumor effect can reduce macrophage motility, inhibit macrophage infiltration of irradiated tumors, and reduce the extent of metastasis in locally irradiated mice [14]. Besides, TAMs derive from monocytes and have the capacity for differentiation; therefore, a combination therapy blocking differentiation may be required for effective targeting of these cells [129]. Interferon γ may induce recruitment of monocytes/macrophages into the tumor microenvironment but inhibits their differentiation into TAMs in vivo; this effect may reduce the concentration of VEGF and angiogenesis in a tumor [130].

4.2. Regulation of TAM Polarization

TAMs are typically designated as “alternatively activated” noninflammatory M2-type macrophages, in contrast to the “classically activated” inflammatory M1 type. TAMs coexist with tumors and function as an accomplice in the promotion of tumor progression, especially after being programmed and polarized into a proangiogenic/immunosuppressive (M2-like) phenotype by the tumor microenvironment [1, 75]. Unlike Th1 and Th2 cells, M1 and M2 macrophages are not stably differentiated subsets and can switch the phenotype [131]. In this case, TAMs represent an ideal therapeutic target for blocking tumor progression after being reprogrammed and repolarized to express a proimmunity (M1-like) phenotype [132]. Dimethyl sulfoxide can suppress mouse 4T1 breast cancer growth by modulating TAM differentiation [133]. It was found that PA-MSHA can reeducate CD163+ TAMs into M1 macrophages through the TLR4-mediated pathway in MPE [27]. M-CSFR signaling was found to govern the phenotype of M2-like MHC- TAMs, and its blockade results in preferential differentiation of monocytes into M1-like MHC- TAMs [134]. Interferon γ and celecoxib can inhibit lung tumor growth by modulating the M2/M1 macrophage ratio in the tumor microenvironment [135].

4.3. Blocking of Factors and Pathways Associated with the Protumor Function of TAMs

The ability of TAMs to accelerate vessel growth is mediated by increased secretion of several proangiogenic factors. Therapeutic success in blocking these protumor activities in preclinical models and early clinical trials highlighted macrophages as effective targets of combination cancer therapy [136]. It is reported that somatostatin derivate (smsDX) can attenuate the TAM-stimulated proliferation, migration, and invasiveness of prostate cancer via NF-κB regulation [137]. Luteolin can also inhibit recruitment of monocytes and migration of Lewis lung carcinoma cells by suppressing chemokine (C-C motif) ligand 2 expression in TAMs [138]. Besides, it has been shown that a cannabinoid receptor 2 agonist inhibits macrophage-induced EMT in non-small cell lung cancer via downregulation of the EGFR pathway [69].

5. Conclusions

TAMs comprise an important part of the tumor microenvironment, and their mobilization into the tumor microenvironment plays a key role in malignant progression. Studies have shown that TAMs lead to a poor clinical prognosis and promote progression of various tumors; these cells also correlate with an unfavorable outcome following therapy. After accumulation in tumor tissues, TAMs can remodel the tumor microenvironment to promote matrix remodeling and promote tumor growth and increase angiogenesis CSC-associated tumor progression. With rapid progress in the understanding of TAM functions, new therapeutic approaches against tumors have been developed, such as inhibition of TAM recruitment or suppression of TAM survival, regulation of TAM polarization, reprogramming of TAMs into the antitumor M1 phenotype, and blocking of factors and pathways associated with the protumor function of TAMs. Thus, the increasing knowledge about the biological effects of TAMs and the tumor microenvironment may lead to novel cancer therapies.


The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

Qiujun Guo, Zhichao Jin, and Yuan Yuan contributed equally to this work.


This work was supported by the National Twelfth Five-Year Plan for Science and Technology Support Program of China (no. 2014BAI10B01) and the National Natural Science Foundation of China (nos. 81202656, 81273718, 81403346, and 81603610).


  1. V. Gocheva, H.-W. Wang, B. B. Gadea et al., “IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion,” Genes and Development, vol. 24, no. 3, pp. 241–255, 2010. View at: Publisher Site | Google Scholar
  2. A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, “Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy,” European Journal of Cancer, vol. 42, no. 6, pp. 717–727, 2006. View at: Publisher Site | Google Scholar
  3. R. Wang, J. Zhang, S. Chen et al., “Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression,” Lung Cancer, vol. 74, no. 2, pp. 188–196, 2011. View at: Publisher Site | Google Scholar
  4. S. Edin, M. L. Wikberg, P.-A. Oldenborg, and R. Palmqvist, “Macrophages: good guys in colorectal cancer,” OncoImmunology, vol. 2, no. 2, article e23038, 2013. View at: Publisher Site | Google Scholar
  5. T. K. Owonikoko, S. E. Dahlberg, S. A. Khan et al., “A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E2511),” Lung Cancer, vol. 89, no. 1, pp. 66–70, 2015. View at: Publisher Site | Google Scholar
  6. W. H. Wilson, “Treatment strategies for aggressive lymphomas: what works?” Hematology, vol. 2013, no. 1, pp. 584–590, 2013. View at: Google Scholar
  7. D. Li and E. M. O'Reilly, “Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma,” Seminars in Oncology, vol. 42, no. 1, pp. 134–143, 2015. View at: Publisher Site | Google Scholar
  8. K. Sugimura, H. Miyata, K. Tanaka et al., “High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer,” Journal of Surgical Oncology, vol. 111, no. 6, pp. 752–759, 2015. View at: Publisher Site | Google Scholar
  9. B. X. Pei, B. S. Sun, Z. F. Zhang, A. L. Wang, and P. Ren, “Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small cell lung cancer,” Journal of Thoracic & Cardiovascular Surgery, vol. 148, no. 4, pp. 1208–1216, 2014. View at: Google Scholar
  10. M. Amit and Z. Gil, “Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase,” OncoImmunology, vol. 2, no. 12, Article ID e27231, 2013. View at: Publisher Site | Google Scholar
  11. C. Yang, L. He, P. He et al., “Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway,” Medical Oncology, vol. 32, no. 2, pp. 1–8, 2015. View at: Publisher Site | Google Scholar
  12. Q.-J. Xuan, J.-X. Wang, A. Nanding et al., “Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients,” Pathology and Oncology Research, vol. 20, no. 3, pp. 619–624, 2014. View at: Publisher Site | Google Scholar
  13. F.-T. Chung, K.-Y. Lee, C.-W. Wang et al., “Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer,” International Journal of Cancer, vol. 131, no. 3, pp. E227–E235, 2012. View at: Publisher Site | Google Scholar
  14. J. S. Russell and J. M. Brown, “The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery,” Frontiers in Physiology, vol. 4, article 157, 2013. View at: Publisher Site | Google Scholar
  15. M. Timaner, R. Bril, O. Kaidar-Person et al., “Dequalinium blocks macrophage-induced metastasis following local radiation,” Oncotarget, vol. 6, no. 29, pp. 27537–27554, 2015. View at: Publisher Site | Google Scholar
  16. T. A. Wynn, A. Chawla, and J. W. Pollard, “Macrophage biology in development, homeostasis and disease,” Nature, vol. 496, no. 7446, pp. 445–455, 2013. View at: Publisher Site | Google Scholar
  17. L. Milas, J. Wike, N. Hunter, J. Volpe, and I. Basic, “Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability,” Cancer Research, vol. 47, no. 4, pp. 1069–1075, 1987. View at: Google Scholar
  18. S. L. Shiao, B. Ruffell, D. G. DeNardo, B. A. Faddegon, C. C. Park, and L. M. Coussens, “TH2-polarized CD4+ T cells and macrophages limit efficacy of radiotherapy,” Cancer Immunology Research, vol. 3, no. 5, pp. 518–525, 2015. View at: Publisher Site | Google Scholar
  19. C. Guo, A. Buranych, D. Sarkar, P. B. Fisher, and X. Y. Wang, “The role of tumor-associated macrophages in tumor vascularization,” Vasc Cell, vol. 15, no. 8, pp. 917–927, 2013. View at: Google Scholar
  20. A. Teresa Pinto, M. Laranjeiro Pinto, A. Patrícia Cardoso et al., “Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities,” Scientific Reports, vol. 6, Article ID 18765, 2016. View at: Publisher Site | Google Scholar
  21. C. Dong, M. He, W. Tu et al., “The differential role of human macrophage in triggering secondary bystander effects after either gamma-ray or carbon beam irradiation,” Cancer Letters, vol. 363, no. 1, pp. 92–100, 2015. View at: Publisher Site | Google Scholar
  22. C.-S. Chiang, S. Y. Fu, S.-C. Wang et al., “Irradiation promotes an M2 macrophage phenotype in tumor hypoxia,” Frontiers in Oncology, vol. 2, article 89, 2012. View at: Publisher Site | Google Scholar
  23. J. Xu, J. Escamilla, S. Mok et al., “CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer,” Cancer Research, vol. 73, no. 9, pp. 2782–2794, 2013. View at: Publisher Site | Google Scholar
  24. E. I. Ager, S. V. Kozin, N. D. Kirkpatrick et al., “Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy,” Journal of the National Cancer Institute, vol. 107, no. 4, 2015. View at: Publisher Site | Google Scholar
  25. J. M. Gwak, M. H. Jang, D. I. Kim, A. N. Seo, and S. Y. Park, “Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer,” PLoS ONE, vol. 10, no. 4, Article ID e0125728, 2015. View at: Publisher Site | Google Scholar
  26. Z.-Y. Yuan, R.-Z. Luo, R.-J. Peng, S.-S. Wang, and C. Xue, “High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis,” OncoTargets and Therapy, vol. 7, pp. 1475–1480, 2014. View at: Publisher Site | Google Scholar
  27. C.-N. Lin, C.-J. Wang, Y.-J. Chao, M.-D. Lai, and Y.-S. Shan, “The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression,” BMC Cancer, vol. 15, no. 1, article 128, 2015. View at: Publisher Site | Google Scholar
  28. L. Yang, F. Wang, L. Wang et al., “CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients,” Oncotarget, vol. 6, no. 12, pp. 10592–10603, 2015. View at: Publisher Site | Google Scholar
  29. Y. Li, B.-S. Sun, B. Pei et al., “Osteopontin-expressing macrophages in non-small cell lung cancer predict survival,” Annals of Thoracic Surgery, vol. 99, no. 4, pp. 1140–1148, 2015. View at: Publisher Site | Google Scholar
  30. Y.-H. Ni, L. Ding, X.-F. Huang, Y.-C. Dong, Q.-G. Hu, and Y.-Y. Hou, “Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients,” Tumor Biology, vol. 36, no. 7, pp. 5291–5298, 2015. View at: Publisher Site | Google Scholar
  31. K.-F. He, L. Zhang, C.-F. Huang et al., “CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma,” BioMed Research International, vol. 2014, Article ID 838632, 9 pages, 2014. View at: Publisher Site | Google Scholar
  32. S. Wang, M. Sun, C. Gu et al., “Expression of CD163, interleukin-10, and interferon-gamma in oral squamous cell carcinoma: mutual relationships and prognostic implications,” European Journal of Oral Sciences, vol. 122, no. 3, pp. 202–209, 2014. View at: Publisher Site | Google Scholar
  33. I. H. Wei, C. M. Harmon, M. Arcerito, D. F. Cheng, R. M. Minter, and D. M. Simeone, “Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors,” Annals of Surgery, vol. 260, no. 6, pp. 1088–1094, 2014. View at: Publisher Site | Google Scholar
  34. P. Ding, W. Wang, J. Wang, Z. Yang, and L. Xue, “Expression of tumor-associated macrophage in progression of human glioma,” Cell Biochemistry and Biophysics, vol. 70, no. 3, pp. 1625–1631, 2014. View at: Publisher Site | Google Scholar
  35. M. Illemann, O. D. Laerum, J. P. Hasselby et al., “Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer,” Cancer Medicine, vol. 3, no. 4, pp. 855–864, 2014. View at: Publisher Site | Google Scholar
  36. M. Kinouchi, K. Miura, T. Mizoi et al., “Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients,” Hepato-Gastroenterology, vol. 60, no. 121, pp. 83–88, 2013. View at: Publisher Site | Google Scholar
  37. Y.-C. Hou, Y.-J. Chao, H.-L. Tung, H.-C. Wang, and Y.-S. Shan, “Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma,” Cancer, vol. 120, no. 17, pp. 2766–2777, 2014. View at: Publisher Site | Google Scholar
  38. C. Lan, X. Huang, S. Lin et al., “Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer,” Technology in Cancer Research & Treatment, vol. 12, no. 3, pp. 259–267, 2013. View at: Publisher Site | Google Scholar
  39. H. Takayama, K. Nishimura, A. Tsujimura et al., “Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus calmette-guerin instillation,” Journal of Urology, vol. 181, no. 4, pp. 1894–1900, 2009. View at: Publisher Site | Google Scholar
  40. X.-F. Jiang, Q.-L. Tang, X.-M. Shen et al., “Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma,” Pathology Research and Practice, vol. 208, no. 12, pp. 730–735, 2012. View at: Publisher Site | Google Scholar
  41. K. Gollapudi, C. Galet, T. Grogan et al., “Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy,” American Journal of Cancer Research, vol. 3, no. 5, pp. 523–529, 2013. View at: Google Scholar
  42. W. Hu, Y. Qian, F. Yu et al., “Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma,” Oncology Letters, vol. 10, no. 3, pp. 1390–1396, 2015. View at: Publisher Site | Google Scholar
  43. D. W. Scott and C. Steidl, “The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling,” Hematology, vol. 2014, no. 1, pp. 144–150, 2014. View at: Publisher Site | Google Scholar
  44. T. Sasayama, K. Tanaka, T. Mizowaki et al., “Tumor-associated macrophages associate with cerebrospinal fluid interleukin-10 and survival in Primary Central Nervous System Lymphoma (PCNSL),” Brain Pathology, vol. 26, no. 4, pp. 479–487, 2016. View at: Publisher Site | Google Scholar
  45. W. Zhang, L. Wang, D. Zhou, Q. Cui, D. Zhao, and Y. Wu, “Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified,” Leukemia and Lymphoma, vol. 52, no. 1, pp. 46–52, 2011. View at: Publisher Site | Google Scholar
  46. Q.-C. Cai, H. Liao, S.-X. Lin et al., “High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma,” Medical Oncology, vol. 29, no. 4, pp. 2317–2322, 2012. View at: Publisher Site | Google Scholar
  47. Q. Guo, J. Li, and H. Lin, “Effect and molecular mechanisms of traditional Chinese medicine on regulating tumor immunosuppressive microenvironment,” BioMed Research International, vol. 2015, Article ID 261620, 12 pages, 2015. View at: Publisher Site | Google Scholar
  48. J. Kim and J.-S. Bae, “Tumor-associated macrophages and neutrophils in tumor microenvironment,” Mediators of Inflammation, vol. 2016, Article ID 6058147, 11 pages, 2016. View at: Publisher Site | Google Scholar
  49. N. L. Costa, M. C. Valadares, P. P. C. Souza et al., “Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma,” Oral Oncology, vol. 49, no. 3, pp. 216–223, 2013. View at: Publisher Site | Google Scholar
  50. Q. Han, H. Shi, and F. Liu, “CD163+ M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma,” International Immunopharmacology, vol. 34, pp. 101–106, 2016. View at: Publisher Site | Google Scholar
  51. T. Krneta, A. Gillgrass, and A. A. Ashkar, “The influence of macrophages and the tumor microenvironment on natural killer cells,” Current Molecular Medicine, vol. 13, no. 1, pp. 68–79, 2013. View at: Publisher Site | Google Scholar
  52. Q.-J. Guo and J. Li, “The role of tumor-associated macrophages in remodeling tumor immune microenvironment,” Tumor, vol. 33, no. 10, pp. 922–927, 2013. View at: Publisher Site | Google Scholar
  53. M. C. Schmid and J. A. Varner, “Myeloid cells in tumor inflammation,” Vascular Cell, vol. 4, article no. 14, 2012. View at: Publisher Site | Google Scholar
  54. M. Lohela, A.-J. Casbon, A. Olow et al., “Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 47, pp. E5086–E5095, 2014. View at: Publisher Site | Google Scholar
  55. P. C. Rodriguez, D. G. Quiceno, J. Zabaleta et al., “Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses,” Cancer Research, vol. 64, no. 16, pp. 5839–5849, 2004. View at: Publisher Site | Google Scholar
  56. T. Lu, R. Ramakrishnan, S. Altiok et al., “Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice,” Journal of Clinical Investigation, vol. 121, no. 10, pp. 4015–4029, 2011. View at: Publisher Site | Google Scholar
  57. A. Kondo, T. Yamashita, H. Tamura et al., “Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes,” Blood, vol. 116, no. 7, pp. 1124–1131, 2010. View at: Publisher Site | Google Scholar
  58. S. I. Grivennikov and M. Karin, “Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. i104–i108, 2011. View at: Publisher Site | Google Scholar
  59. D. M. Mosser and J. P. Edwards, “Exploring the full spectrum of macrophage activation,” Nature Reviews Immunology, vol. 8, no. 12, pp. 958–969, 2008. View at: Publisher Site | Google Scholar
  60. F. Balkwill, K. A. Charles, and A. Mantovani, “Smoldering and polarized inflammation in the initiation and promotion of malignant disease,” Cancer Cell, vol. 7, no. 3, pp. 211–217, 2005. View at: Publisher Site | Google Scholar
  61. F. R. Balkwill and A. Mantovani, “Cancer-related inflammation: common themes and therapeutic opportunities,” Seminars in Cancer Biology, vol. 22, no. 1, pp. 33–40, 2012. View at: Publisher Site | Google Scholar
  62. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at: Publisher Site | Google Scholar
  63. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at: Publisher Site | Google Scholar
  64. H. A. Smith and Y. Kang, “The metastasis-promoting roles of tumor-associated immune cells,” Journal of Molecular Medicine, vol. 91, no. 4, pp. 411–429, 2013. View at: Publisher Site | Google Scholar
  65. J. Condeelis and J. W. Pollard, “Macrophages: obligate partners for tumor cell migration, invasion, and metastasis,” Cell, vol. 124, no. 2, pp. 263–266, 2006. View at: Publisher Site | Google Scholar
  66. H. Wang, X. Wang, X. Li et al., “CD68+HLA-DR+ M1-like macrophages promote motility of HCC cells via NF-κB/FAK pathway,” Cancer Letters, vol. 345, no. 1, pp. 91–99, 2014. View at: Publisher Site | Google Scholar
  67. T. H. Xu, L. Wei, Y. Zhang et al., “Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner,” Bmc Cancer, vol. 14, no. 5, pp. 697–710, 2014. View at: Publisher Site | Google Scholar
  68. B.-Z. Qian, J. Li, H. Zhang et al., “CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis,” Nature, vol. 475, no. 7355, pp. 222–225, 2011. View at: Publisher Site | Google Scholar
  69. T. Kitamura, B.-Z. Qian, D. Soong et al., “CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages,” Journal of Experimental Medicine, vol. 212, no. 7, pp. 1043–1059, 2015. View at: Publisher Site | Google Scholar
  70. Q. Chen, X. H.-F. Zhang, and J. Massagué, “Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs,” Cancer Cell, vol. 20, no. 4, pp. 538–549, 2011. View at: Publisher Site | Google Scholar
  71. B. D. Robinson, G. L. Sica, Y.-F. Liu et al., “Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination,” Clinical Cancer Research, vol. 15, no. 7, pp. 2433–2441, 2009. View at: Publisher Site | Google Scholar
  72. J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-mesenchymal transitions in development and disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009. View at: Publisher Site | Google Scholar
  73. D. K. Gupta, N. Singh, and D. K. Sahu, “TGF-β mediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma,” Cancer Growth & Metastasis, vol. 7, no. 7, pp. 1–8, 2014. View at: Google Scholar
  74. M. De Palma and C. E. Lewis, “Macrophage regulation of tumor responses to anticancer therapies,” Cancer Cell, vol. 23, no. 3, pp. 277–286, 2013. View at: Publisher Site | Google Scholar
  75. C.-Y. Liu, J.-Y. Xu, X.-Y. Shi et al., “M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway,” Laboratory Investigation, vol. 93, no. 7, pp. 844–854, 2013. View at: Publisher Site | Google Scholar
  76. J. Ravi, M. Elbaz, N. A. Wani, M. W. Nasser, and R. K. Ganju, “Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway,” Molecular Carcinogenesis, 2016. View at: Publisher Site | Google Scholar
  77. L. Lin, Y.-S. Chen, Y.-D. Yao et al., “CCL18 from tumor-associated macrophages promotes angio-genesis in breast cancer,” Oncotarget, vol. 6, no. 33, pp. 34758–34773, 2015. View at: Publisher Site | Google Scholar
  78. B. R. Zetter, “Angiogenesis and tumor metastasis,” Annual Review of Medicine, vol. 49, no. 7170, pp. 407–424, 1998. View at: Publisher Site | Google Scholar
  79. X. Xia, R. Du, L. Zhao, W. Sun, and X. Wang, “Expression of AEG-1 and microvessel density correlates with metastasis and prognosis of oral squamous cell carcinoma,” Human Pathology, vol. 45, no. 4, pp. 858–865, 2014. View at: Publisher Site | Google Scholar
  80. S. Karaman and M. Detmar, “Mechanisms of lymphatic metastasis,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 922–928, 2014. View at: Publisher Site | Google Scholar
  81. S. A. Stacker, S. P. Williams, T. Karnezis, R. Shayan, S. B. Fox, and M. G. Achen, “Lymphangiogenesis and lymphatic vessel remodelling in cancer,” Nature Reviews Cancer, vol. 14, no. 3, pp. 159–172, 2014. View at: Publisher Site | Google Scholar
  82. Y. Yang, M. Sun, L. Wang, and B. Jiao, “HIFs, angiogenesis, and cancer,” Journal of Cellular Biochemistry, vol. 114, no. 5, pp. 967–974, 2013. View at: Publisher Site | Google Scholar
  83. J. M. Breuss and P. Uhrin, “VEGF-initiated angiogenesis and the uPA/uPAR system,” Cell Adhesion and Migration, vol. 6, no. 6, pp. 535–540, 2012. View at: Publisher Site | Google Scholar
  84. D. P. Toomey, J. F. Murphy, and K. C. Conlon, “COX-2, VEGF and tumour angiogenesis,” Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland, vol. 7, no. 7, pp. 174–180, 2009. View at: Google Scholar
  85. I. F. Dunn, O. Heese, and P. M. Black, “Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs,” Journal of Neuro-Oncology, vol. 50, no. 1-2, pp. 121–137, 2000. View at: Publisher Site | Google Scholar
  86. E. Fagiani and G. Christofori, “Angiopoietins in angiogenesis,” Cancer Letters, vol. 328, no. 1, pp. 18–26, 2013. View at: Publisher Site | Google Scholar
  87. E.-J. Yeo, L. Cassetta, B.-Z. Qian et al., “Myeloid wnt7b mediates the angiogenic switch and metastasis in breast cancer,” Cancer Research, vol. 74, no. 11, pp. 2962–2973, 2014. View at: Publisher Site | Google Scholar
  88. E. I. Deryugina, E. Zajac, A. Juncker-Jensen, T. A. Kupriyanova, L. Welter, and J. P. Quigley, “Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment,” Neoplasia, vol. 16, no. 10, pp. 771–788, 2014. View at: Publisher Site | Google Scholar
  89. G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003. View at: Publisher Site | Google Scholar
  90. E. I. Deryugina and J. P. Quigley, “Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1803, no. 1, pp. 103–120, 2010. View at: Publisher Site | Google Scholar
  91. A. Casazza, D. Laoui, M. Wenes et al., “Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity,” Cancer Cell, vol. 24, no. 6, pp. 695–709, 2013. View at: Publisher Site | Google Scholar
  92. L. J. Mu, J. S. Wang, Y. Z. Chen et al., “Hypoxia-inducible factor-1α and semaphorin4d genes involved with tumor-associated macrophage-induced metastatic behavior and clinical significance in colon cancer,” Chinese Medical Journal, vol. 127, no. 20, pp. 3568–3575, 2014. View at: Publisher Site | Google Scholar
  93. D. Laoui, E. Van Overmeire, G. Di Conza et al., “Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population,” Cancer Research, vol. 74, no. 1, pp. 24–30, 2014. View at: Google Scholar
  94. L. D. E. Jensen, R. Cao, E.-M. Hedlund et al., “Nitric oxide permits hypoxia-induced lymphatic perfusion by controlling arterial-lymphatic conduits in zebrafish and glass catfish,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 43, pp. 18408–18413, 2009. View at: Publisher Site | Google Scholar
  95. S. Liao and T. P. Padera, “Lymphatic function and immune regulation in health and disease,” Lymphatic Research and Biology, vol. 11, no. 3, pp. 136–143, 2013. View at: Publisher Site | Google Scholar
  96. S. G. Rockson, “Lymphatics: where the circulation meets the immune system,” Lymphatic Research & Biology, vol. 11, no. 3, p. 115, 2013. View at: Publisher Site | Google Scholar
  97. J. Wang, Y. Guo, B. Wang et al., “Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature,” Molecular Biology Reports, vol. 39, no. 12, pp. 11153–11165, 2012. View at: Publisher Site | Google Scholar
  98. Y. Chen, J. Yan, Z. Wang et al., “A meta-analysis of the relationship between lymphatic microvessel density and the survival of patient with colorectal cancer,” Lymphology, vol. 46, no. 1, pp. 42–51, 2013. View at: Google Scholar
  99. I. Pastushenko, P. B. Vermeulen, F. J. Carapeto et al., “Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis,” British Journal of Dermatology, vol. 170, no. 1, pp. 66–77, 2014. View at: Publisher Site | Google Scholar
  100. J. Wang, K. Li, B. Wang, and J. Bi, “Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature,” Molecular Biology Reports, vol. 39, no. 5, pp. 5331–5338, 2012. View at: Publisher Site | Google Scholar
  101. S. F. Schoppmann, A. Fenzl, K. Nagy et al., “VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival,” Surgery, vol. 139, no. 6, pp. 839–846, 2006. View at: Publisher Site | Google Scholar
  102. B. Zhang, G. Yao, Y. Zhang et al., “M2-Polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma,” Clinics, vol. 66, no. 11, pp. 1879–1886, 2011. View at: Publisher Site | Google Scholar
  103. S. F. Schoppmann, P. Birner, J. Stöckl et al., “Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis,” The American Journal of Pathology, vol. 161, no. 3, pp. 947–956, 2002. View at: Publisher Site | Google Scholar
  104. Z. Špirić, Ž. Eri, and M. Erić, “Significance of vascular endothelial growth factor (VEGF)-C and VEGF-D in the progression of cutaneous melanoma,” International Journal of Surgical Pathology, vol. 23, no. 8, pp. 629–637, 2015. View at: Publisher Site | Google Scholar
  105. H. Kurahara, S. Takao, K. Maemura et al., “M2-Polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pn0 pancreatic cancer,” Pancreas, vol. 42, no. 1, pp. 155–159, 2013. View at: Publisher Site | Google Scholar
  106. Y.-F. Sun, Y. Xu, X.-R. Yang et al., “Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection,” Hepatology, vol. 57, no. 4, pp. 1458–1468, 2013. View at: Publisher Site | Google Scholar
  107. Z. Zhen, J. Ren, and M. O'Neil, “Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation,” Bmc Cancer, vol. 12, no. 1, pp. 2604–2615, 2012. View at: Google Scholar
  108. M. Jinushi, S. Chiba, H. Yoshiyama et al., “Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 30, pp. 12425–12430, 2011. View at: Publisher Site | Google Scholar
  109. S. Schwitalla, A. A. Fingerle, P. Cammareri et al., “Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties,” Cell, vol. 152, no. 1-2, pp. 25–38, 2013. View at: Publisher Site | Google Scholar
  110. J. Yang, D. Liao, C. Chen et al., “Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine egfr/stat3/sox-2 signaling pathway,” Stem Cells, vol. 31, no. 2, pp. 248–258, 2013. View at: Publisher Site | Google Scholar
  111. C. Zhang, X. Hu, X. Y. Liu et al., “Effect of tumor-associated macrophages on gastric cancer stem cell in omental milky spots and lymph node micrometastasis,” International Journal of Clinical & Experimental Pathology, vol. 8, no. 11, 2015. View at: Google Scholar
  112. Q.-M. Fan, Y.-Y. Jing, G.-F. Yu et al., “Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma,” Cancer Letters, vol. 352, no. 2, pp. 160–168, 2014. View at: Publisher Site | Google Scholar
  113. X.-Z. Ye, S.-L. Xu, Y.-H. Xin et al., “Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway,” Journal of Immunology, vol. 189, no. 1, pp. 444–453, 2012. View at: Publisher Site | Google Scholar
  114. H. Lu, K. R. Clauser, W. L. Tam et al., “A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages,” Nature Cell Biology, vol. 16, no. 11, pp. 1105–1117, 2014. View at: Publisher Site | Google Scholar
  115. X. Deng, P. Zhang, T. Liang, S. Deng, X. Chen, and L. Zhu, “Ovarian cancer stem cells induce the M2 polarization of macrophages through the PPARγ and NF-κB pathways,” International Journal of Molecular Medicine, vol. 36, no. 2, pp. 449–454, 2015. View at: Publisher Site | Google Scholar
  116. M. Jinushi, “Role of cancer stem cell-associated inflammation in creating pro-inflammatory tumorigenic microenvironments,” OncoImmunology, vol. 3, no. 5, Article ID e28862, 2014. View at: Publisher Site | Google Scholar
  117. T. Chen, X. Wang, L. Guo et al., “Embryonic stem cells promoting macrophage survival and function are crucial for teratoma development,” Frontiers in Immunology, vol. 5, article 275, 2014. View at: Publisher Site | Google Scholar
  118. C. D. Mills, L. L. Lenz, and R. A. Harris, “A breakthrough: macrophage-directed cancer immunotherapy,” Cancer Research, vol. 76, no. 3, pp. 513–516, 2016. View at: Publisher Site | Google Scholar
  119. C. Zhang, L. Gao, Y. Cai et al., “Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model,” Innovation & Social Process, vol. 84, no. 9, pp. 127–136, 2016. View at: Google Scholar
  120. S. Vinogradov, G. Warren, and X. Wei, “Macrophages associated with tumors as potential targets and therapeutic intermediates,” Nanomedicine, vol. 9, no. 5, pp. 695–707, 2014. View at: Publisher Site | Google Scholar
  121. D. Laoui, E. Van Overmeire, P. De Baetselier, J. A. Van Ginderachter, and G. Raes, “Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression,” Frontiers in Immunology, vol. 5, no. 5, article 489, 2014. View at: Publisher Site | Google Scholar
  122. V. Chitu and E. R. Stanley, “Colony-stimulating factor-1 in immunity and inflammation,” Current Opinion in Immunology, vol. 18, no. 1, pp. 39–48, 2006. View at: Publisher Site | Google Scholar
  123. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher et al., “CSF-1R inhibition alters macrophage polarization and blocks glioma progression,” Nature Medicine, vol. 19, no. 10, pp. 1264–1272, 2013. View at: Publisher Site | Google Scholar
  124. C. H. Ries, M. A. Cannarile, S. Hoves et al., “Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy,” Cancer Cell, vol. 25, no. 6, pp. 846–859, 2014. View at: Publisher Site | Google Scholar
  125. F. Roth, A. C. De La Fuente, J. L. Vella, A. Zoso, L. Inverardi, and P. Serafini, “Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression,” Cancer Research, vol. 72, no. 6, pp. 1373–1383, 2012. View at: Publisher Site | Google Scholar
  126. P. Allavena, G. Germano, C. Belgiovine, M. D'Incalci, and A. Mantovani, “A drug from the sea that strikes tumor-associated macrophages,” OncoImmunology, vol. 2, no. 6, article e24614, 2013. View at: Publisher Site | Google Scholar
  127. G. Germano, R. Frapolli, C. Belgiovine et al., “Role of macrophage targeting in the antitumor activity of trabectedin,” Cancer Cell, vol. 23, no. 2, pp. 249–262, 2013. View at: Publisher Site | Google Scholar
  128. L. Leanza, M. Zoratti, E. Gulbins, and I. Szabò, “Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels,” Current Medicinal Chemistry, vol. 19, no. 31, pp. 5394–5404, 2012. View at: Publisher Site | Google Scholar
  129. R. A. Franklin and M. O. Li, “Ontogeny of tumor-associated macrophages and its implication in cancer regulation,” Trends in Cancer, vol. 2, no. 1, pp. 20–34, 2016. View at: Publisher Site | Google Scholar
  130. S. Tao, Y. Ye, L. Xiaoguang et al., “Inhibition of tumor angiogenesis by interferon-γ by suppression of tumor-associated macrophage differentiation,” Oncology Research Featuring Preclinical & Clinical Cancer Therapeutics, vol. 21, no. 5, pp. 227–235, 2014. View at: Google Scholar
  131. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, “Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes,” Trends in Immunology, vol. 23, no. 11, pp. 549–555, 2002. View at: Publisher Site | Google Scholar
  132. T. Chanmee, P. Ontong, K. Konno, and N. Itano, “Tumor-associated macrophages as major players in the tumor microenvironment,” Cancers, vol. 6, no. 3, pp. 1670–1690, 2014. View at: Publisher Site | Google Scholar
  133. R. Deng, S.-M. Wang, T. Yin et al., “Dimethyl sulfoxide suppresses mouse 4T1 breast cancer growth by modulating tumor-associated macrophage differentiation,” Journal of Breast Cancer, vol. 17, no. 1, pp. 25–32, 2014. View at: Publisher Site | Google Scholar
  134. E. Van Overmeire, B. Stijlemans, F. Heymann et al., “M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment,” Cancer Research, vol. 76, no. 1, pp. 35–42, 2016. View at: Publisher Site | Google Scholar
  135. F. Ren, M. Fan, J. Mei et al., “Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment,” Drug Design, Development and Therapy, vol. 8, pp. 1527–1538, 2014. View at: Publisher Site | Google Scholar
  136. R. Noy and J. Pollard, “Tumor-associated macrophages: from mechanisms to therapy,” Immunity, vol. 41, no. 1, pp. 49–61, 2014. View at: Publisher Site | Google Scholar
  137. Z. Guo, Z. Xing, X. Cheng et al., “Somatostatin derivate (smsDX) attenuates the TAM-stimulated proliferation, migration and invasion of prostate cancer via NF-κB regulation,” PLoS ONE, vol. 10, no. 5, Article ID e0124292, 2015. View at: Publisher Site | Google Scholar
  138. H.-J. Choi, H.-J. Choi, T.-W. Chung, and K.-T. Ha, “Luteolin inhibits recruitment of monocytes and migration of Lewis lung carcinoma cells by suppressing chemokine (C-C motif) ligand 2 expression in tumor-associated macrophage,” Biochemical and Biophysical Research Communications, vol. 470, no. 1, pp. 101–106, 2016. View at: Publisher Site | Google Scholar

Copyright © 2016 Qiujun Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

3232 Views | 2918 Downloads | 34 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.